Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Leksum LLC holds a company patent portfolio in the Biotechnology & Pharmaceuticals technology area. The portfolio currently features 1 pending office action. This 1 pending office action is being reviewed by 1 distinct examiner, BAEK, BONG-SOOK. The prosecution is situated within 1 distinct art unit, reflecting a specific focus for the company's current biotechnology filings.
BAEK, BONG-SOOK is identified as the busiest examiner for this portfolio. This examiner is handling 1 busiest examiner pending office action, which represents the totality of the company's active workload at the USPTO. The 1 to 1 ratio of pending actions to examiners indicates that there is no diversification in the current examination pool. The 1 distinct art unit suggests a singular technical classification for the pending matter.
For a patent practitioner, the success of the 1 pending office action depends entirely on the interaction with the 1 distinct examiner. The concentration in 1 distinct art unit means the company is not currently navigating multiple departmental standards. The status of the Biotechnology & Pharmaceuticals portfolio is tied to the resolution of this single active case.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BAEK, BONG-SOOK | 1 | 41.7% | +69.9% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18581843 | EXTRACELLULAR VESICLES FOR THERAPY | BAEK, BONG-SOOK | 72d overdue |
| Art Unit | Apps |
|---|---|
| 1611 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18581843 | EXTRACELLULAR VESICLES FOR THERAPY | BAEK, BONG-SOOK | 1611 | §102§103§112DP | Final Rejection | 72d overdue | Pending | Feb 20, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial